Press Release: Novartis announces positive -2-

Classification to Identify Unmet Clinical Needs and Future Clinical

Goals. Blood 2019;134(Suppl 1):3517.

3. Schubart A, et al. Small-molecule factor B inhibitor for the

treatment of complement-mediated diseases. Proc Natl Acad Sci U S A

2019;116(16):7926--7931.

4. Merle NS, et al. Complement system part II: role in immunity.

Front Immunol 2015;6:257.

5. Risitano AM, et al. Anti-complement Treatment for Paroxysmal

Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A

Position Paper From the SAAWP of the EBMT. Front Immunol 2019;10:1157.

6. Hill A, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis

Primers 2017;3:17028.

7. Risitano AM and Rotoli B. Paroxysmal nocturnal hemoglobinuria:

pathophysiology, natural history and treatment options in the era of

biological agents. Biologics 2008;2(2):205--222.

8. Hill A, et al. Eculizumab prevents intravascular hemolysis in

patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level

extravascular hemolysis occurring through C3 opsonization. Haematologica

2010;95(4):567--573.

9. Schrezenmeier H, et al. Baseline characteristics and disease

burden in patients in the International Paroxysmal Nocturnal

Hemoglobinuria Registry. Haematologica 2014;99(5):922--929.

10. Novartis. Data on file.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Michael Billings

Novartis Global Media Relations Novartis Hematology Communications

+41 61 324 2279 (direct) +1 862 778 8656 (direct)

+41 79 392 8697 (mobile) +1 201 400 1854 (mobile)

anja.von_treskow@novartis.com michael.billings@novartis.com

Eric Althoff Phil McNamara

Novartis US External Communications Novartis Cardio-Metabolic Communications

+1 646 438 4335 +1 862 778 0218 (direct)

eric.althoff@novartis.com +1 862 274 5255 (mobile)

philip.mcnamara@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

August 29, 2020 06:30 ET (10:30 GMT)